{"nctId":"NCT01703221","briefTitle":"Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)","startDateStruct":{"date":"2012-10-24","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":414,"armGroups":[{"label":"Omarigliptin 25 mg (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin","Drug: Placebo to sitagliptin"]},{"label":"Sitagliptin (Phase A) switching to Omarigliptin (Phase B)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Sitagliptin","Drug: Placebo to omarigliptin"]},{"label":"Placebo (Phase A) switching to Omarigliptin (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Placebo to omarigliptin","Drug: Placebo to sitagliptin"]}],"interventions":[{"name":"Omarigliptin","otherNames":[]},{"name":"Sitagliptin","otherNames":["Januvia®"]},{"name":"Placebo to omarigliptin","otherNames":[]},{"name":"Placebo to sitagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has type 2 diabetes mellitus\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* History of any of the following medications: thiazolidinediones and/or insulin within 12 weeks prior to study participation, omarigliptin and/or sitagliptin anytime","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24","description":"HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":null},{"groupId":"OG001","value":"-0.65","spread":null},{"groupId":"OG002","value":"0.13","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event During Phase A","description":"An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"65.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event During the Overall Study","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. These results represent the accrual of events over different treatment intervals: 52 weeks, omarigliptin (Phase A+B) defined as the double-blind period and open label extension period versus 28 weeks for the Sitagliptin (Phase A)→Omarigliptin (Phase B) and placebo (Phase A)→Omarigliptin (Phase B) group defined as the open-label extension period only.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"56.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. These results represent the accrual of events over different treatment intervals: 52 weeks, omarigliptin (Phase A+B) defined as the double-blind period and open label extension period versus 28 weeks for the Sitagliptin (Phase A)→Omarigliptin (Phase B) and placebo (Phase A)→Omarigliptin (Phase B) group defined as the open-label extension period only.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline for 2-hour Post Meal Glucose (PMG) at Week 24","description":"Change from baseline at Week 24 is defined as PMG at Week 24 minus PMG at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.38","spread":null},{"groupId":"OG001","value":"-45.24","spread":null},{"groupId":"OG002","value":"-5.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline for Fasting Plasma Glucose (FPG) at Week 24","description":"Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.52","spread":null},{"groupId":"OG001","value":"-20.75","spread":null},{"groupId":"OG002","value":"-6.23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":166},"commonTop":["Nasopharyngitis"]}}}